



NDA 21-119/S-022

SUPPLEMENT APPROVAL

QLT Inc.
c/o QLT Plug Delivery, Inc.
Attention: David Baker
1098 Hamilton Court
Menlo Park, CA 94025

Dear Mr. Baker:

Please refer to your Supplemental New Drug Application (sNDA) dated March 6, 2008, received March 7, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Visudyne (verteporfin for injection).

We acknowledge receipt of your amendments dated December 16, 2008, and April 17, 2009.

The April 17, 2009, submission constituted a complete response to our September 4, 2008, action letter.

This "Changes Being Effected" supplemental new drug application provides for updates to the PRECAUTIONS/Nursing Mothers section and the addition of the term "retinal pigment epithelial tear" to the ADVERSE REACTIONS section of the package insert.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions regarding this supplemental application, please call Ms. Leanna M. Kelly, Consumer Safety Officer, at (301) 796-0471. For all other inquiries regarding this NDA, please call Ms. Diana Willard, Chief, Project Management Staff, at (301) 796-0833.

Sincerely,

{See appended electronic signature page}

Wiley A. Chambers, M.D.
Deputy Director
Division of Transplant and Ophthalmology Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

WILEY A CHAMBERS
06/28/2012